Johnson & Johnson JNJ
NYSE JNJ
$255.52 +2.24 (+0.88%)
As of: Oct 16, 2026 · 3:59 PM EDT

Johnson & Johnson (JNJ) Income from Non-Controlling Interests (2012)

Updated

Johnson & Johnson's Income from Non-Controlling Interests was -$339 million in FY2012.

Analysis

Johnson & Johnson (JNJ) Income from Non-Controlling Interests (2012) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Inc. Minority (Qtr)
1 Eli Lilly 1,122.91 Bn 1,091.50 Bn 19.71 Bn -
2 Johnson & Johnson 615.09 Bn 533.62 Bn 17.26 Bn -
3 AbbVie 504.75 Bn 477.86 Bn 12.70 Bn 3.00 Mn
4 Merck 360.18 Bn 314.55 Bn 12.21 Bn -2.00 Mn
5 Novartis Ag 292.05 Bn 256.04 Bn 11.24 Bn -7.00 Mn
6 Astrazeneca 256.09 Bn 229.78 Bn 12.86 Bn 1.00 Mn
7 Amgen 233.63 Bn 189.02 Bn 7.24 Bn -
8 Gilead Sciences 194.49 Bn 168.69 Bn 6.22 Bn -
9 Pfizer 168.35 Bn 114.99 Bn 10.94 Bn 10.00 Mn
10 Vertex Pharmaceuticals 126.70 Bn 98.70 Bn 2.84 Bn -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2012 -339.00 Mn
API Access

Johnson & Johnson Income from Non-Controlling Interests API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=income-from-non-controlling-interests&ticker=JNJ&period=max&api_key=YOUR_API_KEY